PITU is designed to temporarily isolate and transport patients with confirmed or suspected COVID-19 infection.
Arrowhead Medical Center Head of Anesthesiology, Dr. Mark Comunale, worked on developing the unit in 2015 after the outbreak of Ebola. AR Tech joined Dr. Comunale's efforts two years ago.
Currently, PITU is ready for use with FDA Emergency Use Authorization on the frontline in the battle against the novel Coronavirus.
PITU protects medical professionals, patients, and visiting family members against respiratory droplets and infection by using a negative pressure enclosure which surrounds the patient.
Patients can be treated by medical staff, and family members who are properly attired can even visit those patients.
A and R Tarpaulins Inc. is the parent company of AR Tech and AR Industries and provides products and services for medical companies, flight hardware, and ground support to various aerospace companies providing satellite launches.
A and R Tarpaulins also provides architectural products and services for homes and businesses, and industrial products for the transportation industry.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA